ArticleGut and liver2026
Muscle Mass as a Causal Factor in MASLD: Insights from a Genome-Wide Association Study and Bidirectional Mendelian Randomization Using Data from the Korean Genome and Epidemiology Study.
Article in Gut and liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging global health concern due to its increasing prevalence and associated risk of severe complications. Although body composition, such as fat and muscle mass, has been linked to MASLD, evidence on the causality of this relationship remains limited. This study investigated the potential causal relationships between body composition and MASLD using epidemiological methods. Methods: Data from the Korean Genome and Epidemiology Study were analyzed. MASLD patients were defined according to the hepatic steatosis index (≥36) and the fibrosis 4 index (≥1.30); individuals with both of these values in normal ranges were considered nonpatients. Body composition was assessed according to fat mass, muscle mass, and the waist-to-hip ratio using bioelectrical impedance analysis. Genome-wide association studies were conducted to identify single-nucleotide polymorphisms (SNPs) linked to body composition and MASLD. These SNPs were then used as instrumental variables in bidirectional Mendelian randomization (MR) analysis to determine causality. Results: A total of 258 MASLD patients and 3,498 nonpatients were included. The MR analysis showed that individuals in the lowest tertile of muscle mass had a higher prevalence of MASLD than those in the 2nd and 3rd tertiles (odds ratio, 1.57; 95% confidence interval, 1.09 to 2.27; p=0.02), whereas the reverse causal effect of MASLD on muscle mass was not significant. No significant causal relationships were identified between fat mass or the waist-to-hip ratio and MASLD, although these analyses were limited by several statistical constraints, such as relatively low F-statistics and potential heterogeneity. Conclusions: The findings demonstrate that muscle mass exerts a causal effect on the prevalence of MASLD, suggesting that modulating muscle mass could serve as an effective strategy for managing the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.